Physician profile
Tejas Gowda
NPI 1073185807
$1,154.41
in general payments reported to CMS, 2019-2025
10 companies · $588 in 2025
The $588 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $31.52 · 2023: $254 · 2024: $280 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093 · Travel and Lodging: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.89 |
| Travel and Lodging | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $423.09 | 2023-2025 | Xywav |
| Abbvie INC. | $145.90 | 2023 | |
| Argenx US, INC. | $143.10 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Octapharma USA, INC. | $135.52 | 2025 | Panzyga |
| Amylyx Pharmaceuticals, INC. | $121.22 | 2024 | Relyvrio |
| Emd Serono, INC. | $75.08 | 2023 | Mavenclad |
| Livanova USA, INC. | $44.91 | 2025 | Vns Therapy, Vns Therapy Symmetry Model 8103 Generator |
| Biogen, INC. | $31.52 | 2022 | |
| Ucb, INC. | $17.90 | 2023 | Briviact |
| Medtronic, INC. | $16.17 | 2024 | Aquamantys(Tm) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejas Gowda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.